GlassScriptPhysician profile
Vineet Mehta
NPI 1508065921
$721.96
in general payments reported to CMS, 2019-2025
13 companies · $34.09 in 2025
The $34.09 reported for 2025 was less than what a typical Addiction Psychiatry provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $42.41 · 2022: $181 · 2023: $208 · 2024: $53.40 · 2025: $34.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $209.86 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $127.23 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $89.45 | 2019-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.78 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $49.12 | 2019-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $39.46 | 2019 | |
| Axsome Therapeutics, INC. | $32.37 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $31.00 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $21.31 | 2022 | |
| Cardiva Medical, INC. | $19.76 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Idorsia Pharmaceuticals US INC | $15.86 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $14.88 | 2025 | Fanapt |
| Adlon Therapeutics L.P. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineet Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.